Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry.

Goebell, P.J., Staehler, M., Müller, L., Nusch, A., Scheffler, M., Sauer, A., von Verschuer, U., Tech, S., Kruggel, L., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Clin. Genitourin. Cancer. 16, e1101-e1115.https://doi.org/10.1016/j.clgc.2018.06.006

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Clinical Genitourinary Cancer
TNK
2018
Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.

Goebell, P.J., Müller, L., Hübner, A., Harich, H.-D., Boller, E., Koska, M., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Urol. Oncol. 36, 470.e1-470.e9. https://doi.org/10.1016/j.urolonc.2018.07.007

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
TNK
2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Niemeier, B., Harde, J., Hannig, C.V., Harich, H.-D., Müller, J., Klausmann, M., Tessen, H.W., Potthoff, K., 2018.

Eur J Haematol 101(6), 766–773. doi:10.1111/ejh.13160

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
PIAZA
2018
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, T., Wolf, T., Schleicher, J., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2018.

Oncol Res Treat 41 (suppl4)(P602), 201-202.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2018
705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal:
NABUCCO
2018
Molekulare Testung, Häufigkeiten molekularer Alterationen und zielgerichtete Erstlinientherapie bei Patienten mit Nicht-kleinzelligem Lungenkarzinom in Deutschland. Ergebnisse der prospektiven Registerplattform CRISP (AIO-TRK-0315).

Griesinger F.; Eberhardt W.; Nusch A.; Reiser M.; Bernhardt C.; Marschner N.; Jänicke M.; Fleitz A.; Spring L.; Sahlmann J.; Karatas A.; Hipper A.; Weichert W.; Rittmeyer A.; Bischoff H.; Waller C.F.; Sebastian M.; Thomas M.; 2018.

Oncol Res Treat 2018;41(suppl 4):1–358

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2018
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: BMC Cancer
REASON
2018
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel, S., Steffens, C.-C., Meyer, D., Tesch, H., Kruggel, L., Frank, M., Jänicke, M., Marschner, M. 2017.

Breast Cancer, 4 December 2017, 1–9. https://doi.org/10.1007/s12282-017-0823-7.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer
TMK
2017
Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Losem, C., Ketzler-Henkel, Zahn, M., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., deWit, M., Metzenmacher, M., Waller, C., Kern, J., Weichert, W., Sebastian, M., Thomas, M., 2017.

IASLC World Conference (Yokohama) (P3.01-088).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: IASLC (WCLC) / Journal: -
CRISP
2017
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Schirmacher, P., Sebastian, M., Thomas, M., 2017.

7th European Lung Cancer Conference (ELCC) (125P).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ELCC (IASLC) / Journal: -
CRISP
2017